Correlation of multidrug-resistance gene (MDR1) expression levels and outcome to adjuvant cisplatin/MTX based chemotherapy in patients enrolled in the AUO-AB 05/95 phase III trial

• Hoffman, A. C. University Hospital Essen, West German Cancer Center, Essen, Germany; ETH Zürich, Zürich, Switzerland; University of Erlangen, Erlangen, Germany; Response Genetics Inc., Los Angeles, CA; University of Southern California, Los Angeles, CA; University of Saarland, Saarland, Germany; Urology Office Kiel, Kiel, Germany
• Wild, P. University Hospital Essen, West German Cancer Center, Essen, Germany; ETH Zürich, Zürich, Switzerland; University of Erlangen, Erlangen, Germany; Response Genetics Inc., Los Angeles, CA; University of Southern California, Los Angeles, CA; University of Saarland, Saarland, Germany; Urology Office Kiel, Kiel, Germany
• Gauler, T. University Hospital Essen, West German Cancer Center, Essen, Germany; ETH Zürich, Zürich, Switzerland; University of Erlangen, Erlangen, Germany; Response Genetics Inc., Los Angeles, CA; University of Southern California, Los Angeles, CA; University of Saarland, Saarland, Germany; Urology Office Kiel, Kiel, Germany
• Leicht, C. University Hospital Essen, West German Cancer Center, Essen, Germany; ETH Zürich, Zürich, Switzerland; University of Erlangen, Erlangen, Germany; Response Genetics Inc., Los Angeles, CA; University of Southern California, Los Angeles, CA; University of Saarland, Saarland, Germany; Urology Office Kiel, Kiel, Germany
• Bertz, S. University Hospital Essen, West German Cancer Center, Essen, Germany; ETH Zürich, Zürich, Switzerland; University of Erlangen, Erlangen, Germany; Response Genetics Inc., Los Angeles, CA; University of Southern California, Los Angeles, CA; University of Saarland, Saarland, Germany; Urology Office Kiel, Kiel, Germany
• Danenberg, K. D. University Hospital Essen, West German Cancer Center, Essen, Germany; ETH Zürich, Zürich, Switzerland; University of Erlangen, Erlangen, Germany; Response Genetics Inc., Los Angeles, CA; University of Southern California, Los Angeles, CA; University of Saarland, Saarland, Germany; Urology Office Kiel, Kiel, Germany
• Danenberg, P. V. University Hospital Essen, West German Cancer Center, Essen, Germany; ETH Zürich, Zürich, Switzerland; University of Erlangen, Erlangen, Germany; Response Genetics Inc., Los Angeles, CA; University of Southern California, Los Angeles, CA; University of Saarland, Saarland, Germany; Urology Office Kiel, Kiel, Germany
• Stöhr, R. University Hospital Essen, West German Cancer Center, Essen, Germany; ETH Zürich, Zürich, Switzerland; University of Erlangen, Erlangen, Germany; Response Genetics Inc., Los Angeles, CA; University of Southern California, Los Angeles, CA; University of Saarland, Saarland, Germany; Urology Office Kiel, Kiel, Germany
• Stöckle, M. University Hospital Essen, West German Cancer Center, Essen, Germany; ETH Zürich, Zürich, Switzerland; University of Erlangen, Erlangen, Germany; Response Genetics Inc., Los Angeles, CA; University of Southern California, Los Angeles, CA; University of Saarland, Saarland, Germany; Urology Office Kiel, Kiel, Germany
• Lehmann, J. University Hospital Essen, West German Cancer Center, Essen, Germany; ETH Zürich, Zürich, Switzerland; University of Erlangen, Erlangen, Germany; Response Genetics Inc., Los Angeles, CA; University of Southern California, Los Angeles, CA; University of Saarland, Saarland, Germany; Urology Office Kiel, Kiel, Germany
• Hartmann, A. University Hospital Essen, West German Cancer Center, Essen, Germany; ETH Zürich, Zürich, Switzerland; University of Erlangen, Erlangen, Germany; Response Genetics Inc., Los Angeles, CA; University of Southern California, Los Angeles, CA; University of Saarland, Saarland, Germany; Urology Office Kiel, Kiel, Germany

Cancer Research

Oncology